DPP4 and COVID-19: A study in 432 diabetics found that the risk of pneumonia was markedly higher in Dipeptidyl peptidase-4 (DPP-4) inhibitor users, but no association was found between oral anti-diabetics use and COVID-19 related mortality [29].